Skip to main content

Table 2 Univariate analysis of factors influencing the overall survival of the 214 PAC patients

From: Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer

Factors Data (n) Median survival (months) 95% CI of median 1 year 3 years P-value
Age (years)       0.068
  ≤65 (130) 16.08 13.23 to 18.93 26.6 15.3  
  >65 (26) 10.28 9.05 to 11.53 16.8 12.0  
Sex       0.020
  Male (125) 11.18 8.51 to 13.85 18.3 8.6  
  Female (89) 16.57 14.05 to 19.09 29.9 23.1  
Symptoms       0.007
  Positive (209) 13.05 10.30 to 15.50 21.2 12.4  
  Negative (5) NA   80.0 80.0  
Bilirubin (mg/dl)       0.009
  ≤1.3 (73) 17.39 12.19 to 22.59 26.7 26.9  
  >1.3 (130) 12.69 10.14 to 15.24 20.9 8.2  
Albumin (g/dl )       0.024
  ≤3.5 (54) 9.04 5.50 to 12.58 15.2 10.2  
  >3.5 (117) 15.75 12.45 to 19.05 25.4 16.7  
Amylase (U/L)       0.216
  ≤300 (82) 13.05 8.77 to 17.33 19.3 13.4  
  >300 (12) 19.27 0.00 to 63.26 50.0 10.0  
Lipase (U/L)       0.255
  ≤300 (47) 12.26 8.48 to 16.05 13.4 8.9  
  >300 (30) 16.04 6.03 to 26.05 26.7 16.0  
CEA (ng/ml)       0.159
  ≤5 (109) 15.85 12.19 to 19.52 23.8 17.5  
  >5 (52) 10.42 7.04 to 13.80 24.7 6.1  
CA 19–9 (U/ml)       0.044
  ≤37 (44) 19.43 8.50 to 30.37 32.6 22.3  
  >37 (125) 13.05 10.08 to 16.02 19.7 9.6  
Surgical procedure       0.115
  Whipple (119) 12.79 9.90 to 15.69 21.2 10.8  
  PPPD (39) 13.05 7.25 to 18.85 23.7 13.5  
  Others (56) 17.19 11.81 to 22.57 25.1 25.1  
Resection margin (cm)       0.001
  Nontumoral 15.42 13.12 to 17.72 58.8 27.3  
  Tumoral 9.67 8.15 to 11.19 42.1 10.5  
Tumor location       0.096
  Head (152) 12.79 10.34 to 15.24 21.3 11.12  
  Uncinate process (20) 19.13 3.79 to 34.47 32.8 32.8  
  Body (32) 19.27 9.75 to 28.80 22.7 22.7  
  Tail (10) 8.19 2.18 to 14.20 20.0 NA  
Portal vein resection       0.249
  Performed (12) 9.27 0.00 to 19.54 16.7 0.0  
  Not performed (202) 13.45 10.62 to 16.29 23.0 15.1  
Tumor size (cm) < 3 (90) 11.89 11.89 to 17.83 24.6 12.7 0.874
  >3 (116) 8.02 8.02 to 16.30 21.9 14.5  
Nodal status Negative (108) 18.87 14.04 to 23.70 34.0 23.1 <0.0001
  Positive (105) 9.4 7.98 to 10.82 11.1 4.7  
TNM staging I (32) 62.99 18.01 to 107.97 56.7 51.0 <0.0001
  II (76) 15.78 12.77 to 18.79 24.9 12.3  
  III (106) 9.4 7.98 to 10.82 11.1 4.7  
Tumor differentiation Well (76) 26.4 21.09 to 31.77 39.5 28.3 <0.0001
  Moderate (98) 10.32 8.39 to 12.25 14.0 7.9  
  Poor (35) 9.47 5.67 to 13.27 12.1 3.0  
  Undifferentiated (5) 5.46 4.60 to 6.32 40.0 0.0  
Post-op radiotherapy       0.849
  Performed (17) 17.56 10.45 to 24.67 17.6 11.8  
  Not Performed (197) 12.79 9.79 to 15.80 23.1 14.3  
Post-op chemotherapy       
  Performed (119) 14.93 11.70 to 18.16 22.7 10.4  
  Not Performed (95) 10.32 7.44 to 13.20 22.5 19.5  
  1. CEA: carcinoembryonic antigen; CA 19–9: carbohydrate antigen 19–9; NA: not applicable; TNM: tumor, node, metastasis; PPPD: pylorus preserving pancreaticoduodenectomy.